Ruzasvir

SKU: orb1819196

Description

Ruzasvir (MK-8408) is a pan-genotypic, small-molecule NS5A inhibitor for hepatitis C virus (HCV) research. It demonstrates potent antiviral activity in vitro and has been evaluated in preclinical animal models, supporting its investigation for antiviral mechanism and combination therapy studies.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 1613081-64-3
• MW: 947.09
• Purity: 99.93% (May vary between batches)
• Formula: C₄₉H₅₅FN₁₀O₇S
• SMILES: FC1=C2C=3N([C@@H](OC2=CC(=C1)C=4NC(=NC4)[C@H]5N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC5)C=6SC(=NC6)C7CC7)C=8C(C3)=CC(=CC8)C=9NC(=NC9)[C@H]%10N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC%10
• Target: HCV Protease
• Solubility: DMSO:50 mg/mL (52.79 mM)

Bioactivity

• In Vitro:
  Ruzasvir (MK-8408) was developed as a novel NS5A inhibitor to improve upon the potency and barrier to resistance of early compounds. Ruzasvir inhibited HCV RNA replication with 50% effective concentrations (EC50s) of 1 to 4 pM in Huh7 or Huh7.5 cells bearing replicons for HCV genotype 1 (GT1) to GT7. The antiviral activity was modestly (10-fold) reduced in the presence of 40% normal human serum. The interaction of Ruzasvir with an NS3/4A protease inhibitor (grazoprevir) and an NS5B polymerase prodrug (uprifosbuvir) was additive to synergistic, with no evidence of antagonism or cytotoxicity.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Ruzasvir, MK 8408, MK8408, MK-8408, HCV Protease, HCV NS5A, HCVProtease

Compound Identifiers

PubChem CID

91936863